GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Other Current Liabilities

KYTX (Kyverna Therapeutics) Other Current Liabilities : $2.72 Mil (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Other Current Liabilities?

Kyverna Therapeutics's other current liabilities for the quarter that ended in Jun. 2024 was $2.72 Mil.

Kyverna Therapeutics's quarterly other current liabilities declined from Dec. 2023 ($6.33 Mil) to Mar. 2024 ($1.36 Mil) but then increased from Mar. 2024 ($1.36 Mil) to Jun. 2024 ($2.72 Mil).

Kyverna Therapeutics's annual other current liabilities increased from Dec. 2021 ($1.72 Mil) to Dec. 2022 ($1.98 Mil) and increased from Dec. 2022 ($1.98 Mil) to Dec. 2023 ($6.33 Mil).


Kyverna Therapeutics Other Current Liabilities Historical Data

The historical data trend for Kyverna Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Other Current Liabilities Chart

Kyverna Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Other Current Liabilities
- - -

Kyverna Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only - - - - -

Kyverna Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.


Kyverna Therapeutics Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of Kyverna Therapeutics's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Kyverna Therapeutics Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
5980 Horton Street, STE 550, Emeryville, CA, USA, 94608
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR.

Kyverna Therapeutics Headlines